
Conference Coverage
about 18 hours ago
APP-Led Quality Assurance Group Is Feasible, Identifies Safety Eventsabout 22 hours ago
Frontline Vaccine/Pembro Yields PFS Benefit in Advanced MelanomaLatest Content

FDA Approves Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

APP-Led Quality Assurance Group Is Feasible, Identifies Safety Events

Frontline Vaccine/Pembro Yields PFS Benefit in Advanced Melanoma

What an Oncology APP Should Know About Exercise in Cancer Care

T-DXd Yields Durable Benefit Across HER2+ Breast Cancer Subgroups

Shorts







Podcasts
Videos
Continuing Medical Education
All News

Disitamab vedotin/toripalimab improved PFS and OS vs chemotherapy in HER2-expressing advanced urothelial carcinoma, per phase 3 RC48-C016 data.

Treatment for patients with R/R multiple myeloma should be based on the individual patient and their history, said Lisa Hwa Christenson, DNP, APRN, CNP.

Among lymphoma survivors, a multidisciplinary intervention program had a beneficial effect on fatigue and aspects of health-related quality of life.

Twenty-year follow-up demonstrated continued imatinib efficacy in advanced GIST with doubled median overall survival.

Using gender-neutral language is the first step in making a safe space for LGBTQIA+ patients with cancer, explained Al Asante-Facey, PA, MBA.

Supervised physical activity, while feasible, was not shown to affect quality of life or fatigue in patients with metastatic cancer.

Paola Gonzalez, MPAS, PA-C, explains how third-party vendors shape insurance guidelines and what oncology APPs should know when navigating peer-to-peer reviews.

Korie Bigbee, DNP, explains the necessity of survivorship care and how to enact changes to make it more accessible to patients with cancer.

Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.

Adding platinum-based chemotherapy to osimertinib improved overall survival vs osimertinib alone in EGFR-mutated NSCLC, even in high-risk subgroups.

Sevabertinib demonstrated robust, durable responses and manageable safety in both treatment-naive and pretreated patients with HER2-mutant advanced NSCLC.

A patient with breast cancer and generalized anxiety disorder was able to avoid an unnecessary mastectomy with virtual reality, said Kelly Preti, DNP.

A multisite advanced practice optimization model improved patient access through tailored interventions, including redistributing non-APP responsibilities.


























































































